Download Brochure
Table of Content
Get a Price
March 2025
Principal Consultant
Reviewed By
The global progesterone market size is calculated at US$ 1.52 in 2024, will grow to US$ 1.72 billion in 2025, and is projected to reach around US$ 5.05 billion by 2034. The market is expanding at a CAGR of 12.74% between 2025 and 2034. Progesterone is used as a hormone replacement therapy and for other conditions, due to which the progesterone market is growing.
A progestogen is a natural or synthetic chemical that functions similarly to progesterone, attaches to the progesterone receptor, and serves as an agonist. It is also known as progestagen, gestagen, or gestogen. Synthetic substances called progestins, which mimic the effects of progesterone, are essential for a number of medical uses, including postmenopausal hormone replacement treatment and contraception. For many years, progesterone and progestins have been used to treat postmenopausal symptoms, secondary amenorrhea, irregular uterine bleeding, pregnancy maintenance with a risk of miscarriage, and contraception. Depending on their structural makeup or generational categorization, these drugs have different effects when they interact with progesterone receptors.
Design of experiments (DoE) techniques and artificial intelligence (AI) have the ability to transform formulation development design and optimization completely. AI is now playing a significant role and receiving increased attention in various industries including pharmacy. This artificial intelligence technology can accelerate the development of nanomedicines, facilitate informed decision-making for complex issues, and aid in predicting positive outcomes. ANNs utilize learning or training to identify patterns in a dataset and produce predictive models. It may be possible to expedite the development of nanomedicine by using ANN models that can predict the physicochemical characteristics of nanocarriers.
Rising Research and Development
The rise in funding and the number of research and development (R&D) efforts carried out by government and commercial research institutes to discover novel uses of hormone treatment are expected to provide more growth prospects for the worldwide market. Progesterone's effects on postmenopausal and perimenopausal women are being examined in a number of ongoing studies. Understanding the contributing elements, such as the structure of progestin and its binding equation with progesterone receptors, is also of interest to many scientific organizations.
Safety Concerns and Side Effects
In addition to numerous therapeutic side effects, progesterone medications may produce mood swings, breast discomfort, nausea, and dizziness. Additional risks associated with long-term or high-dose progesterone usage include hormone-related cancers and cardiovascular issues. Safety issues and negative responses that limit patient compliance and doctor prescription practices may hinder the market's growth.
Growing Applications of Progesterone
Traditionally recognized for its impact on women's health, progesterone is currently being studied for possible uses outside of reproductive medicine. Progesterone-based treatments, such progesterone receptor modulators (PRMs), are being investigated and examined for hormone receptor-positive breast cancer and endometrial cancer, according to the National Library of Medicine. These treatments target the progesterone receptors found in cancer cells, providing a novel approach to their management. The progesterone market might expand if these trials are successful since they may result in novel progesterone-based medicines for various medical disorders as well as additional progesterone indications.
By formulation, the natural segment held the largest share of the progesterone market in 2024. Both synthetic and natural progesterone are frequently used to treat in-vitro fertilization (IVF) cycles and threatening abortions. The hormone natural progesterone (P4) is necessary for the implantation of embryos and the maintenance of early pregnancy. Bioidentical progesterone comes in a range of forms, including creams, gels, tablets, and injections, and may be tailored to meet the specific requirements of each individual. Beyond treating menopausal symptoms, bioidentical progesterone may also improve mood, libido, and sleep quality while lowering anxiety and despair.
By formulation, the synthetic segment is anticipated to grow at the fastest CAGR in the progesterone market during 2025-2034. Synthetic progestogens are referred to as progestin. Progestins are used to treat a variety of gynecological disorders, including endometriosis, contraception, hormone replacement treatment, and artificial reproduction methods, because of their endometrial action. The creation of progestins that more closely resemble the natural hormone has therefore attracted attention. Progestins are still evolving after being produced over several generations for use in menopausal hormone replacement treatment and contraception.
By route of administration, the injectables segment was dominant in the progesterone market in 2024. Parenteral drug administration might be administered for a number of reasons. Since drugs are absorbed more quickly when administered parenterally than when taken orally, their effects start to manifest sooner. Since they do not pass through the gastrointestinal tract's digestive processes and are processed differently, they have a greater effect than oral medications. The parenteral route may also be used to provide medication to patients who are nauseous or incapable of swallowing.
By route of administration, the oral segment is expected to achieve the fastest CAGR in the progesterone market during the forecast period. The most often used method of administering medication is orally. Because of its numerous benefits, oral administration is the preferred method of medication delivery over alternative administration methods. Safety, patient compliance, simplicity of intake, pain prevention, and adaptability to different medication kinds are some of these benefits. Approximately 60% of well-known, commercially accessible small-molecule medicinal compounds are taken orally. Oral formulations account for approximately 90% of the worldwide market share of all pharmaceutical formulations meant for human use, according to current estimates. Oral administration accounts for over 84% of the top-selling pharmaceutical goods, which are presently valued at $35 billion and growing at a pace of 10% annually.
By application, the menopause segment led the progesterone market and is expected to grow at a significant rate during the forecast period. Some menopausal women may benefit from progesterone medication since progesterone levels decrease throughout the menopause transition. Hormone treatment (HT) is well-established for its ability to alleviate symptoms, enhance quality of life, prevent coronary heart disease, lower the risk of osteoporosis and fractures, and lower mortality. In postmenopausal hormone treatment, progestogen primarily protects the endometrium. Menopause symptoms including mood swings, hot flashes, and night sweats can be efficiently managed with hormone treatment, which includes progestogen and estrogen.
By drug type, the branded segment led the progesterone market in 2024. Pharmaceutical businesses develop and commercialize brand-name pharmaceuticals, commonly referred to as originator drugs. These drugs are copyrighted to guarantee the manufacturer's exclusive rights and frequently go through clinical studies. The degree of trust that customers have in brand-name drugs is one of their primary advantages. Patients are reassured that they are getting the finest care available for their disease because these medications have undergone rigorous clinical studies and been shown to be safe and effective. Additionally, pharmaceutical firms' marketing campaigns aid in increasing public knowledge of specific illnesses and their treatments.
By drug type, the generic segment is expected to be the fastest growing in the progesterone market during the predicted timeframe. Finding reasonably priced and efficient treatment choices is a top concern for many people in a world where healthcare expenses are always rising. This is where generic drugs enter the picture and provide a viable remedy. Patients, legislators, and medical professionals all often express interest in and conversation about generic drugs. These drugs function as substitutes for their name-brand equivalents, offering the same active components and therapeutic benefits at a significantly lower price. A larger population may now obtain essential therapies thanks to their availability, which has completely changed the healthcare environment.
By distribution channel, the hospital pharmacy segment dominated the progesterone market in 2024. Hospital pharmacies are essential to providing patients with high-quality medical treatment. Pharmacists' interventions have been demonstrated to help lower the incidence of adverse drug events, enhance medication adherence, and decrease hospital stays as they become more involved in direct clinical care.
By distribution channel, the online pharmacy segment is expected to be the fastest-growing in the progesterone market during the forecast period. Numerous developments in health care have been brought about by the digital age, such as the rise of telemedicine and online pharmacies, which have completely changed how people engage with medical services. The much streamlined access to therapy is arguably the biggest advantage of telemedicine and online pharmacy. A further benefit for individuals who live in distant places or have mobility challenges is that these services enable patients to acquire prescription drugs and consult with medical professionals from the comfort of their own homes.
North America dominated the progesterone market in 2024. The region's sophisticated healthcare system, substantial R&D efforts, and the broad use of progesterone-based treatments for a range of illnesses are all factors contributing to its high regional market share. In addition, the need for progesterone therapy has increased throughout the continent due to the growing incidence of gynecological conditions such infertility, endometriosis, and irregular menstruation. Progesterone products are now more easily accessible and available because to strategic partnerships between pharmaceutical firms and healthcare providers, which has helped North America capture a sizable portion of the worldwide market.
Every year, over 1.3 million women in the US experience menopause. Early natural menopause, which happens between the ages of 40 and 45, affects around 5% of women. Premature menopause affects 1.4% of Black and Hispanic women compared to 1% of white women. In a similar vein, Black and Hispanic women have early menopause at a rate of 3.7% to 4.1%, whereas white women experience it at 2.9%. Menopausal symptoms affect about 80% of women.
Globally, there are differences in the frequency, intensity, and degree of bothersomeness of menopausal vasomotor symptoms (VMS). In North America, the prevalence of VMS is thought to be between 41% and 77%. In Canada, the typical age at which women naturally go through menopause is 51. According to the Canadian Menopause Society guidelines, the most effective treatment for VMS is hormone therapy (HT) with estrogen alone (for women who had a hysterectomy) or combined with a progestogen (for women who had a uterus). This recommendation is made by the Menopause Society and the Society of Obstetricians and Gynecologists of Canada.
Asia Pacific is estimated to host the fastest-growing progesterone market during the forecast period because medical practitioners are more conscious of the issue and are concentrating more on resolving hormone deficiencies. The Asia-Pacific market is growing due to a number of factors, including a large population base, rising healthcare costs, increased awareness of hormonal disorders and treatment options, the aging population's quick adoption of hormone replacement therapies, and a growing focus on enhancing women's healthcare infrastructure. Over the course of the forecast period, China and India are anticipated to have the largest shares of the APAC market.
For women's health in China, 2024 is a lucky year since it commemorates 30 years after the historic International Conference on Population and Development. As larger societal changes speed up the riches and growth of a nation as big and important as China, promoting women's health in China, as elsewhere, requires respecting women's rights and standing. Over the next five years, China will deploy teams of medical professionals to offer services and assist other developing nations in constructing 100 health projects for women and children.
The Indian government runs a number of programs and projects to increase access to healthcare for everyone in the nation, particularly women, those living in rural areas, and members of the SC/ST community. 14.90 crore cervical cancer screenings for women have been carried out to date. Approximately 49% of all Ayushman cards issued and 48% of all allowed hospital admissions are made by women.
Europe is expected to be significantly growing in the progesterone market during the forecast period. In the European Union, one of the main causes driving the market is the rising prevalence of amenorrhea and irregular uterine bleeding among women. Further driving the growth of the European market are favorable government initiatives supporting women's health, rising demand for hormone replacement therapies and fertility treatments, increased awareness of hormonal imbalances and related disorders, and rising investments in progesterone-based treatment research and development in Europe. During the predicted period, the UK and Germany are expected to control a significant portion of the European area.
Menopause, a serious health disease that is little understood and much less discussed, affects nine million women in Germany. The economic burden of untreated menopausal symptoms in the German workplace was originally calculated by MenoSupport. The results show that these symptoms lead to 40 million sick days every year, which translates into €9.4 billion in expenses.
Nearly four million women between the ages of 45 and 55 are employed in the UK, and women over 50 make up a sizable and steadily increasing portion of the workforce. According to the UK government, promoting the hiring and retention of older women in the workforce requires consideration of women's health, including menopause. This is a component of a larger government initiative to address skills shortages, advance the economy, and assist older people for their well-being and professional achievement.
In May 2024, with one of the broadest product offerings for a variety of ailments and its effective management, the introduction of MemUp reinforced Jagsonpal's dedication to the gynecological market, according to Managing Director Mr. Manish Gupta. He went on to say that the company will keep expanding its footprint in the gynecological category in the upcoming quarters by introducing new and tailored formulations.
By Formulation
By Route of Administration
By Application
By Drug Type
By Distribution Channel
By Region
March 2025
March 2025
March 2025
March 2025
Schedule a Meeting